Clinical trial software provider Clinverse has inked a deal with eClinical Insights to share resources and unite their technologies.
Following fast on the heels of two earlier immuno-oncology partnerships, Incyte has agreed to partner its prolific IDO inhibitor INCB24360 with Bristol-Myers Squibb's marquee PD-1 program for nivolumab. And with just days to go before the start of ASCO, Bristol-Myers also inked a biobucks-packed $1.24 billion deal with South San Francisco-based CytomX to broaden its pipeline of immuno-oncology drugs with up to four new clinical candidates spawned by its next-gen antibody development platform.
Cloud-based data magnate Medidata has signed a deal with TransCelerate BioPharma, a consortium of the world's largest drugmakers, to modernize the way the industry conducts clinical trials.
Germany's Wilex is emptying its pockets of drug candidates, giving 5 once-promising cancer treatments back to partner UCB as it pares down to stay alive.
Reckitt Benckiser Pharmaceuticals announced May 19 that it is codeveloping what would be the first nasally administered naloxone-based therapy to treat emergency cases of opioid overdose from heroin or prescription painkillers.
Germany's Orgentec Diagnostika has drawn in Water Street Healthcare Partners as a major investor, which has plans in place to grow the 25-year-old specialty diagnostics company through future M&A deals down the line.
Enigma disclosed it will team up with China's National Institute for Communicable Disease Control and Prevention to develop new rapid, easy-to-use molecular diagnostic tests and tools designed to spot infectious disease pathogens.
France's Servier has struck up a deal with Novartis to develop oncology drugs that invade tumors and lead them to self-destruct.
GE Healthcare and MRI software provider CorTechs Labs signed a joint-marketing agreement on a MRI scanning solution used in conjunction with CorTech's NeuroQuant program.
Amid concerns that its planned buyout of AstraZeneca would deal a blow to U.K. R&D, Pfizer has teamed up with a host of British universities to collaborate on rare-disease drugs.